We are a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. We market in the United States BRAFTOVITM tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E mutation. Our lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications including a Phase 3 trial in BRAF-mutant colorectal cancer (CRC). Our pipeline includes several additional programs being advanced by us or current license-holders including selumetinib (partnered with AstraZeneca), larotrectinib (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797 (being developed by Yarra Therapeutics, a wholly-owned subsidiary of Array), all of which are currently in registration trials. Ganovo® (danoprevir, partnered with Roche and licensed by Roche to Ascletis Pharmaceuticals Co. Ltd. in China) was recently approved in China for the treatment of viral hepatitis C.
Company profile
Website
CEO
Ron Squarer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
841460811
Latest filings (excl ownership)
15-12B
Securities registration termination
9 Aug 19
EFFECT
Notice of effectiveness
1 Aug 19
EFFECT
Notice of effectiveness
1 Aug 19
EFFECT
Notice of effectiveness
1 Aug 19
EFFECT
Notice of effectiveness
1 Aug 19
EFFECT
Notice of effectiveness
1 Aug 19
EFFECT
Notice of effectiveness
1 Aug 19
EFFECT
Notice of effectiveness
1 Aug 19
EFFECT
Notice of effectiveness
1 Aug 19
EFFECT
Notice of effectiveness
1 Aug 19
Transcripts
Latest ownership filings
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|